Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.

To report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy.
Two hundred sixty-three Chinese patients with primary open-angle glaucoma and ocular hypertension who needed initial or additional intraocular pressure (IOP) lowering were recruited in this prospective, open-label, multicenter clinical study and were treated with bimatoprost 0.03%. Patients received bimatoprost 0.03% as initial, replacement or adjunctive IOP-lowering therapy, and follow-up visits were performed at week 1, and month 1 and 3 of the bimatoprost treatment. The efficacy outcome measure was the post-treatment IOP level. The safety outcome measures included the rate of medication-related symptoms, physical signs, reported adverse events, and the level of conjunctival hyperemia.
Among 240 patients who could be categorized by pre-existing therapies and the bimatoprost therapy regimen in the study, IOP values observed in all medication conditions showed significant IOP reduction at all study visits compared with baseline. At 3 months, 8.0 ± 3.7 mmHg (32.0%) reduction in IOP was observed in treatment-naive patients after bimatoprost monotherapy; in the patients previously on various therapy regimens, 1.9 ± 2.8 mmHg (9.5%) to 6.4 ± 6.1 mmHg (24.8%) additional IOP lowering was achieved after switching to bimatoprost monotherapy or bimatoprost combination therapy. The most common adverse event was conjunctival hyperemia, mainly of trace and mild intensity.
Our results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients.
AuthorsKaidi Wang, Li Xu, Zhilan Yuan, Ke Yao, Junmei Zhao, Liang Xu, Aiwu Fang, Mingzhi Zhang, Lingling Wu, Jian Ji, Jiamin Hou, Qing Liu, Xinghuai Sun
JournalBMC ophthalmology (BMC Ophthalmol) Vol. 14 Pg. 21 (Feb 25 2014) ISSN: 1471-2415 [Electronic] England
PMID24568617 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Amides
  • Antihypertensive Agents
  • Cloprostenol
  • Bimatoprost
  • Adult
  • Aged
  • Amides (adverse effects, pharmacology, therapeutic use)
  • Antihypertensive Agents (adverse effects, pharmacology, therapeutic use)
  • Bimatoprost
  • China
  • Cloprostenol (adverse effects, analogs & derivatives, pharmacology, therapeutic use)
  • Conjunctival Diseases (chemically induced)
  • Female
  • Glaucoma, Open-Angle (drug therapy, physiopathology)
  • Humans
  • Hyperemia (chemically induced)
  • Intraocular Pressure (drug effects, physiology)
  • Male
  • Middle Aged
  • Ocular Hypertension (drug therapy, physiopathology)
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: